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Abstract
From 1972 to 2000, 1714 renal transplants were registered in Hong Kong. Forty-two post-transplant
malignancies were reported. The overall incidence of malignancy was 2.4%. The risk ratio was
4.8 when compared with the general population. The corresponding ratio for females is higher. The
majority of the malignancies developed within the first five post-transplant years, especially the
first year, but the cumulative probability of developing malignancy increased with time. The overall
mortality and malignancy related mortality were 40.5% and 33.3% respectively. Post-transplant
lymphoproliferative disease (PTLD), hepatocellular carcinoma (HCC) and Kaposi's sarcoma accounted
for 28.6%, 14.3% and 7.1% of all the tumors and were the major causes of malignancy related
deaths. Two groups of PTLD were observed. Those PTLD developed within the first post-transplant
year had aggressive disease and high mortality. Extra-nodal involvement was found in 75% of
patients, the commonest of which being the graft and the brain. Disseminated disease and central
nervous system (CNS) involvement carried the worst prognosis. HCC was related to hepatitis B
antigen positivity. Routine screening of serum alpha-fetoprotein was helpful in early diagnosis and
treatment, thus favoring the outcome. Kaposi's sarcoma was highly related to the over-
immunosuppressive state. Withdrawal or reduction of immunosuppression may induce complete
remission at the cost of graft loss.
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INTRODUCTION
Renal transplantation program was started in Hong Kong
in 1969 and had become a regular activity since the mid-
80s. The sharing of kidneys among hospitals was
coordinated by the Tissue Typing Laboratory. It also
collected data of the post-transplant malignancies and
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transplant and 27 had two. The male to female ratio was
3:2 .The  median  age  a t  t ransp lan ta t ion  was
37.5 years (ranging from 6.9-72.7 years) and median
follow-up period 64.6 months (ranging from 0-334.4
months). The total follow-up time was 9385.8 patient
years.
INCIDENCE AND MORTALITY
A total of 42 malignancies were reported in 42 patients.
Of them, 22 were males and 20 females. All had their
first renal graft. The overall incidence was 2.4%. The
median age at diagnosis of malignancies was 45.3 years
(ranging from 23.3-65.1 years), which was much younger
than the median age of 65 in the general population. The
median post-transplant duration at the time of diagnosis
of malignancies was 57.3 months (ranging from
0.4-280.4 months). Of all the malignancies, 31% were
diagnosed within the first post-transplant year and
57% within the first  5 years.  Post-transplant
lymphoproliferative disease (PTLD) and Kaposi's
sarcoma were the two earliest developed post-transplant,
whereas the others were developed much later (Fig. 1).
The cumulative risk for post-transplant malignancies was
1.4%, 2.3%, 2.7%, 5.7% and 21.4% at 5, 10, 15, 20 and
25 or more years after renal transplantation respectively
(Fig. 2).
The relative risk of developing a malignancy in the renal
transplant recipients was increased for all ages and the
overall risk ratio was 4.8 when compared with the general
population. For those tumors causing death, females had
an even higher risk of 4.9 than the males' (3.5). After a
median follow-up of 32.6 months (ranging from
2.3-122.9 months), 17 patients died, of whom 14 died of
related tumors. The overall and malignancy related
mortalities were 40.5% and 33.3% respectively. The
median survival time was 2.3 months (ranging from 1-
49.9 months) for those who died of related malignancies.
Despite a higher risk of malignancies in females, the
mortality was lower than that of the male counterpart
(Table 1).
TYPE OF MALIGNANCIES
In 42 patients, 17 types of malignancy were reported
(Table 2). PTLD, hepatocellular carcinoma (HCC) and
Kaposi's sarcoma accounted for 28.6%, 14.3% and
7.1% of all the tumors . The corresponding with all
malignancy related deaths were 35.7%, 14.3% and
7.1%, respectively. The percentage in the general
population was 2.7% and 8.8% respectively for the
former two and was negligible for Kaposi's sarcoma.
(Table 3). No nonmelanoma skin cancer was reported.
The incidence of the commonest cancers in the general
population such as carcinoma of lung, breast, colon,
reported to the Collaborative Transplant Study (CTS).
In 1995, the Hong Kong Registry was implemented in
all the renal dialysis and transplant centers run by the
Hospital Authority, which takes care of 90% to 95% of
all the renal dialysis and transplant patients locally. Since
then, malignancies after renal transplantation were
systemically registered. The data in this report was
obtained from the Tissue Typing Laboratory, the Hong
Kong Renal Registry and the surveys in all the dialysis
and renal transplant centers in Hong Kong, up to end of
March 2000. The data was compared with the Hong Kong
Cancer Registry 1996, the cancer registry for the general
population in Hong Kong.
CLINICAL MATERIAL
From May 1972 to March 2000, 1714 renal transplants
in 1687 patients were registered. Of them, 1660 had one
Figure 1.  The median post-transplant duration at the time of
d iagnos is  o f  ma l ignanc ies .  (PTLD = pos t - t ransp lan t
lymphoproliferative disease; HCC = hepatocellular carcinoma)
Figure 2.  The cumulative chance of malignancies in renal
transplant recipients.
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Of all the transplant recipients, 87% received Cyclosporin
A containing immunosuppressive regimes and 9.2% had
either antilymphocyte globulin (ATG) or monoclonal
OKT3 as induction therapy. Patients who developed
tumors and died of the malignancies had a higher
incidence of severe rejections, thus requiring ATG or
OKT3 (Table 4). However, although there was a trend
Table 1.  The effect of sex on the incidence and mortality of post-transplant malignancies.
Transplant recipient (M:F) General population (M:F)
Overall incidence 1 : 1.38 1.28 : 1
Incidence (exclude sex specific tumors) 1 : 1.15 1.8 : 1
Overall mortality 45.5% : 35%
Cancer mortality 40.9% : 25%
Cancer mortality (exclude sex specific tumors) 42.9% : 31.1%
Table 3.  The percentage of PTLD/lymphoma, HCC and Kaposi's sarcoma in renal transplant recipients and the general population.
Renal transplant recipient General population
% in all malignancies % in all cancer deaths % in all malignancies % in all cancer deaths
PTLD 28.6% 35.7% 2.7% 2.3%
HCC 14.3% 14.3% 8.8% 12.6%
Kaposi's sarcoma 7.1% 7.1% Negligible Negligible
Table 2.  De novo malignancies in renal transplant recipients in Hong Kong.
All malignancies n (%) All deaths n (%) Malignancy related deaths n (%)
PTLD 12 (28.6%) 6 (35.3%) 5 (35.7%)
HCC 6 (14.3%) 3 (17.6%) 2 (14.3%)
Kaposi's sarcoma 3 (7.1%) 1 (5.9%) 1 (7.1%)
Carcinoma of the colon 3 (7.1%) 2 (11.8%) 2 (14.3%)
Carcinoma of the kidney 2 (4.8%) 1 (5.9%) 1 (7.1%)
Carcinoma of the breast 2 (4.8%) 0
Carcinoma of the thyroid 2 (4.8%) 0
Carcinoma of the cervix 2 (4.8%) 0
Carcinoma of the lung 2 (4.8%) 1 (5.9%) 1 (7.1%)
Carcinoma of the urinary bladder 1 (2.4%) 1 (5.9%) 0
Carcinoma of the ureter 1 (2.4%) 0
Carcinoma of the prostate 1 (2.4%) 0
Carcinoma of the stomach 1 (2.4%) 1 (5.9%) 1 (7.1%)
Melanoma 1 (2.4%) 1 (5.9%) 1 (7.1%)
EBV related spindle cell tumor of the graft 1 (2.4%) 0
EBV related smooth muscle tumor 1 (2.4%) 0
Dermatofibrosarcoma protuberant 1 (2.4%) 0
n = 42 n = 17 n = 14
Table 4.  Relationship of rejection with post-transplant malignancies.
All transplants All malignancies All cancer deaths
% with rejection 31.6% 30.9% 41.2%
   1 rejection 78.6% 61.5% 57.1%
   2 rejections 12.5% 23.1% 14.3%
   3 or more rejections 7.9% 15.4% 28.6%
Number of rejection episodes per patient 0.42 0.48 0.71
% of rejection episodes requiring ATG/OKT3 19.2% 20% 25%
% of patients received ATG/OKT3 8.1% 9.5% 17.6%
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Twelve patients had PTLD. The male to female ratio was
1:1. The median post-transplant duration at diagnosis was
10.9 months (ranging from 0.4-131.8 months). The
disease clustered at two time periods: seven patients had
PTLD within the first post-transplant year with an
average of 6 months and five patients were diagnosed at
an average of 8 post-transplant years (Fig.3). Six patients
died. Of them, five died of PTLD. All of these five
patients had their disease developed within the first post-
transplant year and the median survival was 3.9 months
(ranging from 2.1-6.1 months). The relative risk was 72
to 102 times of the general population and PTLD patients
were much younger (Table 5).
Only three patients (25%) had PTLD confined to lymph
nodes. Four (33.3%) had graft and two (16.7%) had brain
involvement. Four (33.3%) had multiple organs
involvement (Table 6). Ten patients (82%) were Epstein-
Barr virus (EBV) antibodies positive. Eleven (91%) had
non-Hodgkin's disease. B-cell markers were found in all
except one patient (91%). In one patient, the PTLD was
confirmed to originate from the donor lymphocytes and
the disease involved the renal graft only.
Eleven patients received Cyclosporin A and one had
Tacrolimus as part of the immunosuppressive regime.
There was a upward trend in the rate of rejection and use
of antilymphocyte antibodies or monoclonal OKT3 in
PTLD patients, especially those who died from the
disease (Table 7).
Cyclosporin A or Tacrolimus were completely stopped
without initial graft nephrectomy in eight patients. Four
patients subsequently developed acute rejection and two
lost their grafts. Two patients (16.7%) had complete
Figure 3.  The time clusters of the PTLD.
Table 5.  The comparison of the PTLD in renal transplant recipients and the lymphoma in general population.
Renal transplant recipient General population
All PTLD PTLD who died All lymphoma Lymphoma who died
% of all cancer 28.6% 35.7% 2.7% 2.3%
Age standardized rate 592.5 234.7 M 8.2 M 3.3
F 5.8 F 2.0
Relative risk 72-102 71-117
Sex (M:F) 1 : 1 1 : 1 1.3 : 1 1.4 : 1
Median age at diagnosis 35.2 M 63
F 65
Median age at death 41 M 65
F 72
Table 6.  Site of involvement of the PTLD.
Organs involved n (%) Organs confined to n (%) Organ involved in general population (%)
Lymph node 5 (41.7%) 3 (25%) 52-76%
Graft 4 (33.3%) 3 (25%)
CNS 2 (16.7%) 1 (8.3%) 1%
Stomach 1 (8.3%) 1 (8.3%)
Disseminated 4 (33.3%) 4 (33.3%)
n =12 n = 12
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remission only after stopping Cyclosporin A or
Tacrolimus. Various treatment modalities including graft
nephrectomy, chemotherapy, radiotherapy and
immunoadsorptive therapy were tried (Table 8). Five
patients (41.7%) died of PTLD but complete remission
was achievable in seven patients (58.3%). Patients with
disease confined to the lymph node had the best outcome
while disseminated disease or brain involvement carried
the worst prognosis (Table 9).
HEPATOCELLULAR CARCINOMA
Six patients were diagnosed to have HCC. The male to
female ratio was 1:1. The median age was 53.3 years
(ranging from 38.1-65.1 years). The median post-
transplant duration at diagnosis was 82.4 months (ranging
from 14.2-191.1 months). Five patients were hepatitis B
antigen positive and all were hepatitis C negative. The
chance of developing HCC amongst the hepatitis B
antigen positive transplant recipients was 3.1% but
became 0.07% if the recipient was hepatitis B antigen
negative. All the three patients who died had their HCC
diagnosed late. The median survival was 3.5 months. The
other three patients were diagnosed early by regular
screening of the serum alpha-fetoprotein. They were
treated either by wedge excision or transarterial
Table 7.  Effect of immunosuppression on PTLD.
All transplant (1714) All malignancies (42) All PTLD (12) PTLD died (5)
% of patients with rejection 31.6% 30.9% 50% 60%
Number of rejection episodes per patient 0.42 0.48 0.92 1.4
% of rejection episodes requiring ATG/OKT3 19.2% 20% 27.3% 42.9%
Table 8.  Treatment modalities for the PTLD.
Treatment Number of Complete remission Organs involved in patients
patients treated with single treatment remission with complete with single treatment
Stop cyclosporin A/tacrolimus 9 2 Lymph node; graft
Graft nephrectomy 2 1 Graft
Chemotherapy 5 1 Stomach
Adoptive immunotherapy 1 1 Liver/spleen/lymph node
Radiotherapy 2 0 CNS
Table 9.  Outcome of the PTLD.
Complete remission 7 (58.3%) Deaths from malignancy 5 (41.7%)
Confined to lymph node 3 (100%) 0
Confined to graft 2 (66.7%) 1 (33.3%)
Confined to stomach 1 (100%) 0
Confined to CNS 0 1 (100%)
*Involvement of the CNS 0 2 (100%)
Disseminated 1 (25%) 3 (75%)
Table 10.  Presentation and outcome of the HCC.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Presentation Abdominal Abdominal Impaired Screened by Screened by Screened by
  pain    pain + septicemia   liver function   αFP   αFP   αFP
Hepatitis B status +ve -ve +ve +ve +ve +ve
Cirrhosis -ve -ve +ve -ve +ve +ve
Treatment Unknown Laparotomy Selective TACE Wedge excision Wedge excision +
  open and close   internal radiation   TACE
Outcome Died of CVA Died of disease Died of disease Alive Alive Alive
Median survival Survival: 3.5 Survival: 3.5 Survival: 3.5 Follow-up : Follow-up: Follow-up:
   or follow-up   months   months   months    32.3 months   32.3 months    32.3 months
αFP = alpha-fetoprotein; TACE = transarterial chemoembolism; CVA = cerebrovascular accident
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chemoembolism or both. All of them survived at a
median follow-up duration of 32.2 months (Table 10).
KAPOSI'S SARCOMA
Two male and one female patients developed Kaposi's
sarcoma. The median age was 51.6 years (ranging from
41.8-54.8 years) and the median post-transplant duration
was 4 months (ranging from 1-5.1 months). All patients
had visceral involvement. One patient died 1.5 months
after the diagnosis despite chemotherapy. The other two
patients had remission of the disease after Cyclosporin
A was stopped or reduced. However, they lost their grafts
after 7 and 30 months respectively.
DISCUSSION
Malignancy complicating organ transplantation is a major
cause of mortality and morbidity. The reported incidence
ranges from 4% to 18%, averaging 6%. The incidence
in Hong Kong is 2.4%. Post-transplant malignancies are
more common in females (1). The commonest cancer
reported is the carcinoma of skin which has a high
prevalence amongst fair skin Caucasians in areas with
high sunlight exposure like Australia and New Zealand.
If carcinoma of skin is excluded, the data in Hong Kong
showed a great similarity with the Cincinnati Transplant
Tumor Registry (CTTR) (2,3) which is the largest post-
transplant tumor registry in the world (Table 11). The
transplant recipients have a much higher risk of
developing malignancies at a much younger age
compared with the general population. The risk is even
more obvious in those tumors related to over-
immunosuppression such as PTLD and Kaposi's
sarcoma. The other uncommon tumors include carcinoma
of the vulva and perineum, lip cancers, carcinoma of
kidney, hepatobiliary tumors and other sarcomas. The
overall incidence increases with time. In Australia, 38%
of renal transplant patients will have at least one skin
cancer at 10 years post-transplant and the estimated
probability for developing a skin cancer is 66% and other
cancers is 27% by 23 years.
Excluding skin cancer, PTLD is the commonest post-
transplant malignancy reported by CTTR and other
registries (2,3). Kaposi's sarcoma is also significant as
its incidence in the general population is practically
negligible. These two tumors are very similar in many
aspects. Both develop early in the post-transplant period.
Both are related to viral infection: EBV in PTLD and
Human Herpes virus 8 in Kaposi's sarcoma. Both are
related to the potency of immunosuppressive treatment
and reduction or withdrawal of immunosuppression alone
may induce complete remission. It is believed that it is
t h e  o v e r a l l  i n t e n s i t y  a n d  d u r a t i o n  o f  t h e
immunosuppression rather than any individual
immunosuppressive agent that causes the increased
chance of these tumors.
The clinical features of the PTLD in Hong Kong are
consistent with those reported by CTTR (2,3). A majority
of the PTLD are B cell in origin and belong to non-
Hodgkin's lymphoma. There is a high incidence of
extranodal involvement, especially with the graft and the
central nervous system (CNS) where the brain is
commonly involved (Table 12). The disease correlates
with the total cumulative immunosuppression and the
number of rejection episodes (4). The disease tends to
be aggressive and develops early, especially when OKT3
is used.
Table 11.  Comparison of the types of malignancies in Hong Kong
with the Cincinnati Transplant Tumor Registry.
HK renal transplant CTTR *
Carcinoma of skin & lip 0% 6%
PTLD 28.6% 24%
HCC 14.3% 2.3%
Kaposi's sarcoma 7.1% 5.7%
Carcinoma of kidney 4.8% 5%
Anogenital carcinoma 0% 3.5%
CTTR* = malignancies excluding nonmelanoma skin cancers and
carcinoma of cervix in situ in all types of organ transplants
Table 12.  Comparison of the PTLD in Hong Kong with the Cincinnati Transplant Tumor Registry.
Hong Kong (12 cases) CTTR* (1595 cases)
EBV antibody positive 83% 90%-95%
B cell lymphoma 91% 85%
T cell lymphoma 9% 15%
Hodgkin's lymphoma 9% <3%
Non-Hodgkin's lymphoma 91% 92%
Extranodal involvement 75% 70%
CNS involvement 16.7% 20%
CNS involvement only 8.3% 11%
Graft involvement 33.3% 23%
CTTR* = PTLD in all types of organ transplants
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Kaposi's sarcoma is especially common among transplant
recipients of African, Arabic, Jewish or Mediterranean
ancestry and accounted for up to 68% of all post-
transplant malignancy in Turkey (1,5). Visceral
involvement  ranges  f rom 24% to  50%. The
gastrointestinal tract, lung and lymph nodes are the
commonest sites involved. The mortality is 46% if
visceral organs are involved but is rare if only skin is
involved. Withdrawal of immunosuppressive is the
mainstay of treatment and it alone can achieve complete
remission in 31% of patients with visceral and 52% with
skin involvement (3).
In areas with high prevalence of Hepatitis B, such as
Taiwan and Japan, HCC is common amongst hepatitis B
antigen positive transplant patients (6). Good prognosis
is associated with early detection and treatment. Routine
serum alpha-fetoprotein is a simple but important
screening test in diagnosing early tumor. Hepatitis C
positivity is less common (6.9%) than hepatitis B
positivity (9.3%) in renal transplant recipients in Hong
Kong. It is also an important cause for post-transplant
HCC as reported in Taiwan.
Skin cancer and anogenital cancer are common
malignancies in other registries (2,3). Skin cancers are
usually multicentric in origin, locally invasive, and can
metastasize and kill. In contrast to the general population,
squamous cell carcinoma is more common than basal
cell carcinoma. The risk factors include skin color,
amount of sun exposure, age and length of post-transplant
period. The anogenital cancer is related to human
papilloma virus (HPV) infection which also causes the
carcinomas of lip and cervix. The reported median post-
transplant duration for skin cancer was 54 months and
anogenital cancer 112 months. The absence of non-
melanoma skin cancer in Hong Kong may be related to
the relatively short follow-up time and racial factor. It is
expected to be of greater significance when the follow-
up period is long enough in the future.
The mainstay of treatment for PTLD, Kaposi's sarcoma
and aggressive/extensive malignancies is reduction or
withdrawal of immunosuppression. Surgical excision is
curative for early tumors. Radiation therapy may be
effective for localized PTLD and Kaposi's sarcoma.
Chemotherapy, interferon-alpha and antiviral agents may
be used for PTLD and Kaposi's sarcoma.
Prophylactic measures including proper clothing,
sunscreens, topical retinoids and hepatitis B vaccination
should be carried out. Life-long surveillance such as Pap-
smear and mammogram for females, alpha-fetoprotein
for hepatitis B positive patients, chest x-ray for smokers
and colonoscopy for patients with family history of
carcinoma of colon are advisable for early detection and
diagnosis of these potentially fatal complications.
Precancerous lesions should be treated vigorously
because of the aggressive behavior of the tumors.
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